Inspire's Azasite Falls Short of Goals in Studies
DURHAM, N.C. (AP) — Inspire Pharmaceuticals Inc. said Monday its potential treatment for inflamed eyelids did not meet key goals in two midstage studies.
In the most extreme form of the condition in which the margins of the eyelids are red and irritated, tiny ulcers can form around the eyes.
The company said that its treatment, Azasite, failed to produce "statistically significant" results in both a four-week and two-week study focusing on the condition, which is known medically as blepharitis.
The company said the midstage studies were designed to "study a variety of endpoints and difference dosing durations to fully understand" Azasite's potential.
"These Phase 2 trials provided us with valuable information to advance our blepharitis program towards a potential labeled indication," President and CEO Adrian Adams said in a statement.
He said the company will conduct additional work with the goal of moving the drug into late-stage, or Phase 3, development.